Roche discontinues phase III GENERATION HD1 study evaluating investigational candidate tominersen in manifest Huntington’s disease

This decision was based on the results of a pre-planned review of the data by an unblinded Independent Data Monitoring Committee on potential risk/benefit profile of this investigational antisense therapy, designed to reduce production of all forms of the huntingtin protein.

Source:

PharmaTimes